Drug repurposing—an emerging strategy in cancer therapeutics
Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, c...
Gespeichert in:
Veröffentlicht in: | Naunyn-Schmiedeberg's archives of pharmacology 2022-10, Vol.395 (10), p.1139-1158 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1158 |
---|---|
container_issue | 10 |
container_start_page | 1139 |
container_title | Naunyn-Schmiedeberg's archives of pharmacology |
container_volume | 395 |
creator | Turabi, Khadija Shahab Deshmukh, Ankita Paul, Sayan Swami, Dayanand Siddiqui, Shafina Kumar, Urwashi Naikar, Shreelekha Devarajan, Shine Basu, Soumya Paul, Manash K. Aich, Jyotirmoi |
description | Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug’s original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline. |
doi_str_mv | 10.1007/s00210-022-02263-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2675981868</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2713092967</sourcerecordid><originalsourceid>FETCH-LOGICAL-c305t-da3eed56eb84ce51afd815a579d67749db3a5cb7d387d03e1756c773f846dd203</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMotlZfwIUMuHEzmktz2whSr1Bwo-uQJqfjlHZmTGag3fkQPqFPYmqrggsX4RDOd_5z-BA6JvicYCwvIsaU4BxTun6C5csd1CdDRnOiCd1F_dRXOaFa9dBBjDOMsSCc76Me40JzTUgfXV6HrsgCNF1o6lhWxcfbu60yWEAo0i-LbbAtFKusrDJnKwcha18g2Aa6tnTxEO1N7TzC0bYO0PPtzdPoPh8_3j2Mrsa5Y5i3ubcMwHMBEzV0wImdekW45VJ7IeVQ-wmz3E2kZ0p6zIBILpyUbKqGwnuK2QCdbXKbUL92EFuzKKOD-dxWUHfRUCG5VkQJldDTP-is7kKVrjNUEoY11UImim4oF-oYA0xNE8qFDStDsFnbNRu7Jpk1X3bNMg2dbKO7yQL8z8i3zgSwDRBTqyog_O7-J_YTxk2GGw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2713092967</pqid></control><display><type>article</type><title>Drug repurposing—an emerging strategy in cancer therapeutics</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Turabi, Khadija Shahab ; Deshmukh, Ankita ; Paul, Sayan ; Swami, Dayanand ; Siddiqui, Shafina ; Kumar, Urwashi ; Naikar, Shreelekha ; Devarajan, Shine ; Basu, Soumya ; Paul, Manash K. ; Aich, Jyotirmoi</creator><creatorcontrib>Turabi, Khadija Shahab ; Deshmukh, Ankita ; Paul, Sayan ; Swami, Dayanand ; Siddiqui, Shafina ; Kumar, Urwashi ; Naikar, Shreelekha ; Devarajan, Shine ; Basu, Soumya ; Paul, Manash K. ; Aich, Jyotirmoi</creatorcontrib><description>Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug’s original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.</description><identifier>ISSN: 0028-1298</identifier><identifier>EISSN: 1432-1912</identifier><identifier>DOI: 10.1007/s00210-022-02263-x</identifier><identifier>PMID: 35695911</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antidiabetics ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Artificial Intelligence ; Biomedical and Life Sciences ; Biomedicine ; Cancer ; Cancer therapies ; Chemotherapy ; Clinical trials ; Computer applications ; Drug development ; Drug discovery ; Drug Repositioning - methods ; Drugs ; Humans ; Neoplasms - drug therapy ; Neurosciences ; Pharmacology/Toxicology ; Proteomics ; Radiation therapy ; Review ; Side effects</subject><ispartof>Naunyn-Schmiedeberg's archives of pharmacology, 2022-10, Vol.395 (10), p.1139-1158</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022</rights><rights>2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c305t-da3eed56eb84ce51afd815a579d67749db3a5cb7d387d03e1756c773f846dd203</citedby><cites>FETCH-LOGICAL-c305t-da3eed56eb84ce51afd815a579d67749db3a5cb7d387d03e1756c773f846dd203</cites><orcidid>0000-0001-6842-5724 ; 0000-0002-6180-3785 ; 0000-0002-0990-7392 ; 0000-0001-6620-950X ; 0000-0002-0889-6767 ; 0000-0002-9404-0024 ; 0000-0002-0372-6435 ; 0000-0002-1726-0154 ; 0000-0002-8840-4768 ; 0000-0003-1252-6942 ; 0000-0003-2133-8011</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00210-022-02263-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00210-022-02263-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35695911$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turabi, Khadija Shahab</creatorcontrib><creatorcontrib>Deshmukh, Ankita</creatorcontrib><creatorcontrib>Paul, Sayan</creatorcontrib><creatorcontrib>Swami, Dayanand</creatorcontrib><creatorcontrib>Siddiqui, Shafina</creatorcontrib><creatorcontrib>Kumar, Urwashi</creatorcontrib><creatorcontrib>Naikar, Shreelekha</creatorcontrib><creatorcontrib>Devarajan, Shine</creatorcontrib><creatorcontrib>Basu, Soumya</creatorcontrib><creatorcontrib>Paul, Manash K.</creatorcontrib><creatorcontrib>Aich, Jyotirmoi</creatorcontrib><title>Drug repurposing—an emerging strategy in cancer therapeutics</title><title>Naunyn-Schmiedeberg's archives of pharmacology</title><addtitle>Naunyn-Schmiedeberg's Arch Pharmacol</addtitle><addtitle>Naunyn Schmiedebergs Arch Pharmacol</addtitle><description>Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug’s original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.</description><subject>Antidiabetics</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Artificial Intelligence</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Computer applications</subject><subject>Drug development</subject><subject>Drug discovery</subject><subject>Drug Repositioning - methods</subject><subject>Drugs</subject><subject>Humans</subject><subject>Neoplasms - drug therapy</subject><subject>Neurosciences</subject><subject>Pharmacology/Toxicology</subject><subject>Proteomics</subject><subject>Radiation therapy</subject><subject>Review</subject><subject>Side effects</subject><issn>0028-1298</issn><issn>1432-1912</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kMtKAzEUhoMotlZfwIUMuHEzmktz2whSr1Bwo-uQJqfjlHZmTGag3fkQPqFPYmqrggsX4RDOd_5z-BA6JvicYCwvIsaU4BxTun6C5csd1CdDRnOiCd1F_dRXOaFa9dBBjDOMsSCc76Me40JzTUgfXV6HrsgCNF1o6lhWxcfbu60yWEAo0i-LbbAtFKusrDJnKwcha18g2Aa6tnTxEO1N7TzC0bYO0PPtzdPoPh8_3j2Mrsa5Y5i3ubcMwHMBEzV0wImdekW45VJ7IeVQ-wmz3E2kZ0p6zIBILpyUbKqGwnuK2QCdbXKbUL92EFuzKKOD-dxWUHfRUCG5VkQJldDTP-is7kKVrjNUEoY11UImim4oF-oYA0xNE8qFDStDsFnbNRu7Jpk1X3bNMg2dbKO7yQL8z8i3zgSwDRBTqyog_O7-J_YTxk2GGw</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Turabi, Khadija Shahab</creator><creator>Deshmukh, Ankita</creator><creator>Paul, Sayan</creator><creator>Swami, Dayanand</creator><creator>Siddiqui, Shafina</creator><creator>Kumar, Urwashi</creator><creator>Naikar, Shreelekha</creator><creator>Devarajan, Shine</creator><creator>Basu, Soumya</creator><creator>Paul, Manash K.</creator><creator>Aich, Jyotirmoi</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6842-5724</orcidid><orcidid>https://orcid.org/0000-0002-6180-3785</orcidid><orcidid>https://orcid.org/0000-0002-0990-7392</orcidid><orcidid>https://orcid.org/0000-0001-6620-950X</orcidid><orcidid>https://orcid.org/0000-0002-0889-6767</orcidid><orcidid>https://orcid.org/0000-0002-9404-0024</orcidid><orcidid>https://orcid.org/0000-0002-0372-6435</orcidid><orcidid>https://orcid.org/0000-0002-1726-0154</orcidid><orcidid>https://orcid.org/0000-0002-8840-4768</orcidid><orcidid>https://orcid.org/0000-0003-1252-6942</orcidid><orcidid>https://orcid.org/0000-0003-2133-8011</orcidid></search><sort><creationdate>20221001</creationdate><title>Drug repurposing—an emerging strategy in cancer therapeutics</title><author>Turabi, Khadija Shahab ; Deshmukh, Ankita ; Paul, Sayan ; Swami, Dayanand ; Siddiqui, Shafina ; Kumar, Urwashi ; Naikar, Shreelekha ; Devarajan, Shine ; Basu, Soumya ; Paul, Manash K. ; Aich, Jyotirmoi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c305t-da3eed56eb84ce51afd815a579d67749db3a5cb7d387d03e1756c773f846dd203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antidiabetics</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Artificial Intelligence</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Computer applications</topic><topic>Drug development</topic><topic>Drug discovery</topic><topic>Drug Repositioning - methods</topic><topic>Drugs</topic><topic>Humans</topic><topic>Neoplasms - drug therapy</topic><topic>Neurosciences</topic><topic>Pharmacology/Toxicology</topic><topic>Proteomics</topic><topic>Radiation therapy</topic><topic>Review</topic><topic>Side effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turabi, Khadija Shahab</creatorcontrib><creatorcontrib>Deshmukh, Ankita</creatorcontrib><creatorcontrib>Paul, Sayan</creatorcontrib><creatorcontrib>Swami, Dayanand</creatorcontrib><creatorcontrib>Siddiqui, Shafina</creatorcontrib><creatorcontrib>Kumar, Urwashi</creatorcontrib><creatorcontrib>Naikar, Shreelekha</creatorcontrib><creatorcontrib>Devarajan, Shine</creatorcontrib><creatorcontrib>Basu, Soumya</creatorcontrib><creatorcontrib>Paul, Manash K.</creatorcontrib><creatorcontrib>Aich, Jyotirmoi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Naunyn-Schmiedeberg's archives of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turabi, Khadija Shahab</au><au>Deshmukh, Ankita</au><au>Paul, Sayan</au><au>Swami, Dayanand</au><au>Siddiqui, Shafina</au><au>Kumar, Urwashi</au><au>Naikar, Shreelekha</au><au>Devarajan, Shine</au><au>Basu, Soumya</au><au>Paul, Manash K.</au><au>Aich, Jyotirmoi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug repurposing—an emerging strategy in cancer therapeutics</atitle><jtitle>Naunyn-Schmiedeberg's archives of pharmacology</jtitle><stitle>Naunyn-Schmiedeberg's Arch Pharmacol</stitle><addtitle>Naunyn Schmiedebergs Arch Pharmacol</addtitle><date>2022-10-01</date><risdate>2022</risdate><volume>395</volume><issue>10</issue><spage>1139</spage><epage>1158</epage><pages>1139-1158</pages><issn>0028-1298</issn><eissn>1432-1912</eissn><abstract>Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug’s original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>35695911</pmid><doi>10.1007/s00210-022-02263-x</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0001-6842-5724</orcidid><orcidid>https://orcid.org/0000-0002-6180-3785</orcidid><orcidid>https://orcid.org/0000-0002-0990-7392</orcidid><orcidid>https://orcid.org/0000-0001-6620-950X</orcidid><orcidid>https://orcid.org/0000-0002-0889-6767</orcidid><orcidid>https://orcid.org/0000-0002-9404-0024</orcidid><orcidid>https://orcid.org/0000-0002-0372-6435</orcidid><orcidid>https://orcid.org/0000-0002-1726-0154</orcidid><orcidid>https://orcid.org/0000-0002-8840-4768</orcidid><orcidid>https://orcid.org/0000-0003-1252-6942</orcidid><orcidid>https://orcid.org/0000-0003-2133-8011</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-1298 |
ispartof | Naunyn-Schmiedeberg's archives of pharmacology, 2022-10, Vol.395 (10), p.1139-1158 |
issn | 0028-1298 1432-1912 |
language | eng |
recordid | cdi_proquest_miscellaneous_2675981868 |
source | MEDLINE; SpringerNature Journals |
subjects | Antidiabetics Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Artificial Intelligence Biomedical and Life Sciences Biomedicine Cancer Cancer therapies Chemotherapy Clinical trials Computer applications Drug development Drug discovery Drug Repositioning - methods Drugs Humans Neoplasms - drug therapy Neurosciences Pharmacology/Toxicology Proteomics Radiation therapy Review Side effects |
title | Drug repurposing—an emerging strategy in cancer therapeutics |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T15%3A44%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20repurposing%E2%80%94an%20emerging%20strategy%20in%20cancer%20therapeutics&rft.jtitle=Naunyn-Schmiedeberg's%20archives%20of%20pharmacology&rft.au=Turabi,%20Khadija%20Shahab&rft.date=2022-10-01&rft.volume=395&rft.issue=10&rft.spage=1139&rft.epage=1158&rft.pages=1139-1158&rft.issn=0028-1298&rft.eissn=1432-1912&rft_id=info:doi/10.1007/s00210-022-02263-x&rft_dat=%3Cproquest_cross%3E2713092967%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2713092967&rft_id=info:pmid/35695911&rfr_iscdi=true |